Publications
2022
A de novo SFMBT1 pathogenic variant identified in a boy with Poland syndrome. Miltiadous A, Demetriou P, Kyriakou M, Gerasimou P, Herodotou G, Elpidoforou A, Kyprianou Y, Iacovou M, Chi J, Costeas P, Tanteles GA. Cold Spring Harb Mol Case Stud. 2022 Apr28.
The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. Dunn WG, Gu MS, Fabre MA, Cooper J, Nomdedeu JF, Koumas L, Nicolaou K, Chi J, Costeas P, Vassiliou GS. Ann Hematol. 2022 Feb.
Pharmacological activation of the C5a receptor leads to stimulation of the beta-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer’s disease. Fella E, Papacharalambous R, Kynigopoulos D, Ioannou M, Derua R, Christodoulou C, Stylianou M, Karaiskos C, Kagiavas A, Gerasimou P, Pierides C, Kyriakou M, Koumas L, Costeas P, Panagiotou E. Frontiers in Immunology. Aug 2022.
Racial/Ethnic Disparities on the Risk of Second Malignant Neoplasm Among Hodgkin Lymphoma Survivors. Xiao H, He J, Liang S, Cai D, Zhou Q, Liu L, Yan X, Chi J, Xiao Q, Wang L. Front Oncol. 2022
Jan 24;11:790891.
2021
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Yankova E., Blackaby W., Albertella M., Rak J., Braekeleer E.D., Tsagkogeorga G., Pilka E.S., Aspris D., Leggate D., Hendrick A.G., Webster N.A., Andrews B., Fosbeary R., Guest P., Irigoyen N., Eleftheriou M., Gozdecka M., Dias J.M.L., Bannister A.J., Vick B., Jeremias I., Vassiliou G.S., Rausch O., Tzelepis K., Kouzarides T. Nature, 2021 May.
The N6-methyladenosine RNA modification in acute myeloid leukemia. Yankova E., Aspris D., Tzelepis K. Curr Opin Hematol., 2021 Mar 1.
Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Yu T, Chi J, Wang L. Hematology. 2021 Dec;26(1):848-859.
Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway. Liang S, Zhou X, Cai D, Rodrigues-Lima F, Chi J, Wang L. Front Cell Dev Biol. 2021 Sep 9;9:685954.
METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Orellana EA, Liu Q, Yankova E, Pirouz M, Braekeleer ED, Zhang W, Lim J, Aspris D, Sendinc E, Garyfallos DA, Gu M, Ali R, Gutierrez A, Mikutis S, Bernardes GJL, Fischer ES, Bradley A, Vassiliou GS, Slack FJ, Tzelepis K, Gregory RI. Mol Cell. 2021 Aug 19;81(16):3323-3338.
Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. Koukoulias K, Papadopoulou A, Kouimtzidis A, Papayanni PG, Papaloizou A, Sotiropoulos D, Yiangou M, Costeas P, Anagnostopoulos A, Yannaki E, Kaloyannidis P. Br J Haematol. 2021 Jul;194(1):158-167.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Agathangelidis A, Chatzidimitriou A, …52 authors…, Costeas P, …27 authors, Stamatopoulos K. Blood. 2021 Mar 11;137(10):1365-1376.
The N6-methyladenosine RNA modification in acute myeloid leukemia. Yankova E, Aspris D, Tzelepis K. Curr Opin Hematol. 2021 Mar 1;28(2):80-85.
2020
Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Mpekris F. Panagi M., Voutouri C., Martin J.D., Samuel R., Takahashi S., Gotohda N., Suzuki T., Papageorgis P., Demetriou P., Pierides C., Koumas L., Costeas P., Kojima M., Ishii G., Constantinidou A., Kataoka K., Cabral H., Stylianopoulos T. Advanced Science, 2020 Dec13.
meCLICK-Seq, a Substrate-Hijacking and RNA Degradation Strategy for the Study of RNA Methylation. Mikutis S., Gu M., Sendinc E., Madoka E. Hazemi, Kiely-Collins H., Aspris D., Vassiliou G.S., Yang Shi, Tzelepis K., and Bernardes G.J.L. ACS Cent Sci. 2020 Dec 23.
The Role of Tumour-Associated Myeloid Cells in Modulating Cancer Therapy. Neophytou MC., Pierides C., Christodoulou MI., Costeas P., Kyriakou TC., Papageorgis. Review article. Front. Oncol., 09 June 2020. https://doi.org/10.3389/fonc.2020.00899
TGF-beta inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, Demetriou P, Pierides C, Polydorou C, Stylianou A, Louca M, Koumas L Costeas P, Kataoka K, Cabral H, Stylianopoulos T.
Theranostics. 2020 Jan 12;10(4):1910-1922.
The rare DNA ligase IV syndrome: A case report. Gerasimou P, Koumas L, Miltiadous A, Kyprianou I, Chi J, Gavrielidou R, Socratous E, Loizou L, Papachristodoulou E, Karaoli E, Loizos A, Anastasiadou V, Costeas P. Human Pathology: Case Reports, Vol, 22, Nov. 2020.
HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia. Cell Death Dis. 2020 Jun 30;11(6):492.
2019
C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer’s disease. Panayiotou E, Fella E, Andreou S, Papacharalambous R, Gerasimou P, Costeas P, Angeli S, Kousiappa I, Papacostas S, Kyriakides T. PLoS One. 2019 Dec 6;14(12):e0225417.
2018
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS. Nat Commun. 2018 Dec 19;9(1):5378.
MicroRNA 143 increases cell apoptosis in myelodysplastic syndrome through the Fas/FasL pathway both in vitro and in vivo. Cui J, Wei C, Deng L, Kuang X, Zhang Z, Pierides C, Chi J, Wang L. Int J Oncol. 2018 Nov;53(5):2191-2199
Combined effect of glutamine at position 70 of HLA-DRB1 and alanine at position 57 of HLA-DQB1 in type 1 diabetes: An epitope analysis. Gerasimou P, Nicolaidou V, Skordis N, Picolos M, Monos D, Costeas PA. PLoS One. 2018 Mar 1;13(3):e0193684
2017
JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. McKerrell T, Park N, Chi J, Collord G, Moreno T, Ponstingl H, Dias J, Gerasimou P, Melanthiou K, Prokopiou C, Antoniades M, Varela I, Costeas PA, Vassiliou GS. Blood Adv. 2017 Jun 12;1(14):968-971.
Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. Stamou P, Marioli D, Patmanidi AL, Sgourou A, Vittoraki A, Theofani E, Pierides C, Taraviras S, Costeas PA, Spyridonidis A.Cytotherapy. 2017 Apr;19(4):521-530
HLA-G variability and haplotypes detected by massively parallel sequencing procedures in the geographicaly distinct population samples of Brazil and Cyprus. Castelli EC, Gerasimou P, Paz MA, Ramalho J, Porto IOP, Lima THA, Souza AS, Veiga-Castelli LC, Collares CVA, Donadi EA, Mendes-Junior CT, Costeas P.Mol Immunol. 2017 Mar;83:115-126.
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R. Leukemia. 2017 Mar;31(3):593-601
2016
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.
Blood. 2016 Jul 7;128(1):e1-9.
HLA-G 14-bp polymorphism affects the age of onset in Type I Diabetes Mellitus.Gerasimou P, Skordis N, Picolos M, Spyridonidis A, Costeas P. Int J Immunogenet. 2016 Jun;43(3):135-42.
2015
Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition, V. Nicolaidou1, C. Stylianou2, L. Koumas, G. S. Vassiliou, K. B. Bodman-Smith & P. Costeas, Tissue Antigens. 2015 Apr;85(4):267-77.
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring. Chi J, Manoloukos M, Pierides C, Nicolaidou V, Nicolaou K, Kleopa M, Vassiliou G, Costeas P. Ann Hematol. 2015 Mar;94(3):399-408. Epub 2014 Oct 29.
The EUTOS population-based registry: Incidence and clinical characteristics of 2 904 CML patients in twenty European Countries, Leukemia. 2015 Mar 18. doi: 10.1038/leu.2015.73. [Epub ahead of print]
cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit. Chi J, Pierides C, Mitsidou A, Miltiadou A, Gerasimou P, Costeas P. Biol Proced Online. 2015 Feb 9;17(1):4. doi: 10.1186/s12575-015-0014-x. eCollection 2015.
2014
A sensitive detection method for MPLW515L or MPLW515K mutation in myeloproliferative disorders. Jianxiang Chi, Chryso Pierides, Andrie Mitsidou, Andrie Miltiadou, Petroula, Gerasimou, Katerina Nicolaou and Paul Costeas. European Journal of Experimental Biology, 2014, 4(5):33-36
Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G, Quail MA, Sathiaseelan V, Herman B, Crawley C, Craig JI, Conte N, Grove C, Papaemmanuil E, Campbell PJ, Varela I, Costeas P, Vassiliou GS. Haematologica. 2015 Feb;100(2):214-22. Epub 2014 Nov 7.
2013
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, Manoloukos M, Barbouti K, Melanthiou F, Prokopiou C, Vassiliou GS, Costeas P. Leukemia. 2014 May;28(5):1152-4. Epub 2013 Dec 24.
Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Segonds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M, Huntly B, Bradley A, Vassiliou GS. Leukemia. 2013 Sep;27(9):1820-5. Epub 2013 Apr 18.
2012
Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells. Nicolaou KA, Liapis V, Evdokiou A, Constantinou C, Magiatis P, Skaltsounis AL, Koumas L, Costeas PA, Constantinou AI. Biochem Biophys Res Commun. 2012 Aug 17;425(1):76-82. Epub 2012 Jul 20.
Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: a case control study. Eftychiou C, Antoniades L, Makri L, Koumas L, Costeas PA, Kyriakou E, Nicolaides E, Papadogiannis D. Hellenic J Cardiol. 2012 May-Jun;53(3):189-94.
Donors as research subjects: a challenge. King R, Schmidt AH, Costeas P, Egeland T. Bone Marrow Transplant. 2012 Apr;47(4):605-6. Epub 2011 Jun 13.
2003-2011
Unrelated hematopoietic stem cell donors as research subjects. King RJ, Confer DL, Greinix HT, Halter J, Horowitz M, Schmidt AH, Costeas P, Shaw B, Egeland T; Ethics and Clinical Working Groups of World Marrow Donor Association. Bone Marrow Transplant. 2011 Jan;46(1):10-3. Epub 2010 Mar 1.
Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A, Greinix H; Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Bone Marrow Transplant. 2008 Jul;42(1):9-14. doi: 10.1038/bmt.2008.76. Epub 2008 Mar 24.
Th2/Th3 cytokine genotypes are associated with pregnancy loss. Costeas PA, Koumouli A, Giantsiou-Kyriakou A, Papaloizou A, Koumas L. Hum Immunol. 2004 Feb;65(2):135-41.
Genetic assessment of cardiovascular risk factors in the Greek Cypriot population. Koumas L, Costeas PA, Papaloizou A, Giantsiou-Kyriakou A. Thromb Res. 2003;112(3):143-6.
Cytokine polymorphism frequencies in the Greek Cypriot population. Costeas PA, Koumas L, Koumouli A, Kyriakou-Giantsiou A, Papaloizou A. Eur J Immunogenet. 2003 Oct;30(5):341-3.